antibody formation
Recently Published Documents


TOTAL DOCUMENTS

1215
(FIVE YEARS 75)

H-INDEX

66
(FIVE YEARS 7)

2022 ◽  
Vol 7 (2) ◽  
Author(s):  
Hakan Sezgin Sayiner ◽  
Aşki Vural ◽  
Fatih Doğan ◽  
Sedat Parlak ◽  
Furkan Bakirhan

There is no effective treatment for the Covid-19 disease that is still impacting the whole world. It considered that vaccines, one of the effective means to prevent infectious diseases, will play a significant role in protecting from the Covid-19 Disease. Vaccinations generals performed before exposure. We aimed to follow the clinical and laboratory progress of patients who got Covid-19 after the first dose of the Covid-19 vaccine and to evaluate the changes that may occur in antibody formation. 13 patients, who received the first dose of COVID 19 vaccine Coronovac as of 14.01.2021 when vaccination started in Adıyaman University Training and Research Hospital/Turkey, who had symptoms after the vaccine and whose real-time PCR found to be positive, were included in the study. After the first dose of the Covid-19 vaccine, 13 patients exam. Three of our patients were female, and 10 of them were male. The average age was 38.8. British variant detected in 4 of our patients; 1 of them was female. Contact times differed between 3 and 5 days. The most common symptoms were muscle-joint pain (53.8), weakness-fatigue (46.2), fever (38.5), and headache (30.8). Three of our patients, being one female, received inpatient treatment. Furthermore, our five patients who checked regarding Sars cov-2 IgG became positive in the first month. No adverse changes in the course of the illness observed in the patients were RT-PCR positive after the first dose of the Covid-19 vaccine. Antibody response detected at the end of the first month.  Vaccination is an effective method for taking infectious diseases under control but adhering to personal protective measures still maintains their importance.


Author(s):  
T. V. Amvrosieva ◽  
I. V. Belskaya ◽  
Z. F. Bohush ◽  
N. V. Paklonskaya ◽  
Yu. B. Kaltunova ◽  
...  

The presented work contains an analysis of seroprevalence, tension, and duration of post-vaccination immunity to the SARS-CoV-2 coronavirus in the residents of the Republic of Belarus after immunization with two vaccine preparations available in the country: Sputnik V and Vero Cell.It was found that seroconversion after the injection of the Vero Cell vaccine occurred significantly later than after the Sputnik V vaccine (p < 0.001). Nevertheless, two-stage immunization with the vaccines provided a sufficiently high efficiency of the inoculated antibodies to the S protein of the COVID-19 pathogen: the proportion of seropositive persons reached 99.19 [96.89; 99.97] % for Sputnik V and 96.03 [90.81; 98.53] % for Vero Cell. The efficiency of antibody formation after immunization with the Vero Cell vaccine was lower in older persons (in the group > 65 years). The proportion of individuals with the highest IgG score for the SARS-CoV-2 S protein was higher after the Sputnik V administration compared to that in response to the Vero Cell vaccine (p < 0.05), and gradually decreased over time. However, no significant decrease in the level of seropositive individuals after 90 days from the start of immunization with the both vaccine preparations was detected. In COVID-19 survivors immunized with the Sputnik V vaccine, the quantitative indicators of post-vaccination antibodies reached their peak values after 1 dose of the vaccine. The obtained results complement the accumulated world science and practical information on the problem of the postvaccination immunity formation in the context of the use of different drugs against COVID-19.>< 0.001). Nevertheless, two-stage immunization with the vaccines provided a sufficiently high efficiency of the inoculated antibodies to the S protein of the COVID-19 pathogen: the proportion of seropositive persons reached 99.19 [96.89; 99.97] % for Sputnik V and 96.03 [90.81; 98.53] % for Vero Cell. The efficiency of antibody formation after immunization with the Vero Cell vaccine was lower in older persons (in the group > 65 years). The proportion of individuals with the highest IgG score for the SARS-CoV-2 S protein was higher after the Sputnik V administration compared to that in response to the Vero Cell vaccine (p < 0.05), and gradually decreased over time. However, no significant decrease in the level of seropositive individuals after 90 days from the start of immunization with the both vaccine preparations was detected. In COVID-19 survivors immunized with the Sputnik V vaccine, the quantitative indicators of post-vaccination antibodies reached their peak values after 1 dose of the vaccine.The obtained results complement the accumulated world science and practical information on the problem of the postvaccination immunity formation in the context of the use of different drugs against COVID-19.


2021 ◽  
pp. 107815522110554
Author(s):  
Meghan Pike ◽  
Ketan Kulkarni ◽  
Tamara MacDonald

Introduction Pegaspargase can cause anti-asparaginase antibody formation, which can decrease its effectiveness without causing any clinically apparent reaction (silent inactivation). When a patient has silent inactivation, a switch to Erwinia anti-asparaginase is warranted, but there is currently a global shortage of Erwinia. The only way to identify silent inactivation is to measure an asparaginase level. However, routine asparaginase level monitoring is not currently standard of care at all Canadian centers. This study aims to identify variations in practice regarding asparaginase level monitoring and Erwinia use. Methods A 21-item survey was developed using OPINIO software and distributed to all Pediatric Hematology–Oncologists in Canada from February to October 2020. Results Respondents represented 15 hospitals across each region of Canada (response rate = 52%). Only 39.2% of respondents reported routinely measuring asparaginase levels, yet 53% of respondents have modified therapy from pegaspargase to Erwinia in up to half of their patients. The most common reason for not measuring asparaginase levels was not knowing how to use levels clinically (25.5%). There was variation in the timing of levels and their target. Conclusions We identified substantial variation in asparaginase activity monitoring practices across Canada. Therefore, future research should aim to develop a national practice guideline on asparaginase activity monitoring.


BioDrugs ◽  
2021 ◽  
Author(s):  
Steven J. Bots ◽  
Claire E. Parker ◽  
Johannan F. Brandse ◽  
Mark Löwenberg ◽  
Brian G. Feagan ◽  
...  

2021 ◽  
Vol 14 (11) ◽  
pp. e245171
Author(s):  
Ritin Mohindra ◽  
Vikas Suri ◽  
Debajyoti Chatterjee ◽  
Kirtan Rana

We present a case of a 51-year-old immunosuppressed man with underlying chronic lymphoproliferative leukaemia (CLL), who presented to us in emergency with breathlessness, hydrophobia, anxiety and restlessness. He had a history of category 3 dog bite 2 months ago and had received a full course of rabies immunoglobulin and antirabies vaccine (ARV) as per the national schedule. As there were frank clinical reports of rabies, the patient was managed according to Milwaukee regimen. The patients died within a week of the appearance of symptoms. The brain autopsy revealed Negri bodies conforming the mortality due to rabies.Immunosuppressed patients, like our patient who had CLL have low antibody formation after rabies prophylaxis. Antibody titres in immunosuppressed patients need to be measured after the 2–4 weeks of the last injection of ARV to decide whether a booster of ARV needs to be administered or not.


2021 ◽  
Vol 141 (10) ◽  
pp. S151
Author(s):  
A. Mennella ◽  
A. Mylonas ◽  
J. Chen ◽  
A. Nidegger ◽  
M. Gilliet ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document